Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 58%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics is expected to continue its strong performance in the IRD space with its robust pipeline and upcoming clinical readouts. The company's strategic approach, including derisking clinical programs, informed prevalence estimates, and careful patient selection, gives it a favorable outlook within the competitive IRD market. With multiple rare pediatric disease vouchers potentially available, Opus has the potential for a significant boost in funding and valuation. Furthermore, the company's focus on inherited retinal diseases with limited competition and potential for high gross margins make it an attractive investment opportunity.

Bears say

Opus Genetics is currently a clinical-stage biopharmaceutical company with a narrow focus on treating inherited retinal diseases, and though it has a diverse pipeline, most of its potential revenue relies on only two lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1. The company's financials show significant losses and a lack of commercial products, meaning it will need substantial funding to continue with its clinical development plans. While there are some positive indicators, such as the FDA agreeing to a streamlined path for OPGx-LCA5 and a partnership with the Abu Dhabi Department of Health for MERTK, there are also significant risks to consider, including potential regulatory hurdles and market competition from other emerging therapies targeting similar diseases. Overall, the narrow focus, lack of commercial products, and potential risks make us outlook negatively on Opus Genetics' stock for now.

Opus Genetics (IRD) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 58% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Buy based on their latest research and market trends.

According to 12 analysts, Opus Genetics (IRD) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.